Anupam Rasayan expects a 30-35 per cent revenue increase in the financial year ending in March 2026 (FY26), driven by rising demand across pharmaceuticals, polymers, and a recovering agrochemical segment
Demand circumstances have greatly improved, according to Deputy CFO Vishal Thakur, especially in agrochemicals, where volumes are increasing. He stated, “We anticipate growth to continue in Q4 and into FY26 as well. The revenue uptake is largely based on volume.”
Agrochemicals made up 49 per cent of overall sales during the nine months that ended in December 2024, with pharmaceuticals coming in second at 23 per cent, personal care at 17 per cent, and performance materials at 11 per cent. It is anticipated that margins will stay steady between 26-28 per cent.
With revenues increasing 32 per cent year over year (YoY) to Rs 390 crore and profits before interest, tax, depreciation, and amortisation (EBITDA) up 57 per cent YoY to Rs 124 crore, the company had a good third quarter. A positive product mix and consistent demand helped margins grow by 500 basis points (bps) to 31.8 per cent. However, compared to the same period last year, revenue was down 13 for the first nine months of the current fiscal year, while profit was down 24 per cent and the margin was 27.5 per cent. Around 9,000 crore worth of orders have been placed by Anupam Rasayan, and fresh contracts are anticipated to begin contributing in 2025.
Projects signed in 2022 are being commercialized by the corporation, and over the next two years, more recent deals will start to ramp up. According to him, it usually takes 18 to 24 months for a letter of intent to become a commercial product, and an additional two to three years for it to achieve full volume. Additionally, Anupam Rasayan is closely monitoring its working capital cycle, which had experienced some upswing earlier this year. Thakur stated that the medium-term goal is still 180–200 days.
